Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse.

Department of Radiation Oncology of Zhongshan hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China.
BMC Cancer (Impact Factor: 3.32). 07/2011; 11:297. DOI: 10.1186/1471-2407-11-297
Source: PubMed

ABSTRACT Since transitional cell carcinoma (TCC) of the upper urinary tract is a relatively uncommon malignancy, the role of adjuvant radiotherapy is unknown.
We treated 133 patients with TCC of the renal pelvis or ureter at our institution between 1998 and 2008. The 67 patients who received external beam radiotherapy (EBRT) following surgery were assigned to the radiation group (RT). The clinical target volume included the renal fossa, the course of the ureter to the entire bladder, and the paracaval and para-aortic lymph nodes, which were at risk of harbouring metastatic disease in 53 patients. The tumour bed or residual tumour was targeted in 14 patients. The median radiation dose administered was 50 Gy. The 66 patients who received intravesical chemotherapy were assigned to the non-radiation group (non-RT).
The overall survival rates for the RT and non-RT groups were not significantly different (p = 0.198). However, there was a significant difference between the survival rates for these groups based on patients with T3/T4 stage cancer. A significant difference was observed in the bladder tumour relapse rate between the irradiated and non-irradiated bladder groups (p = 0.004). Multivariate analysis indicated that improved overall survival was associated with age < 60 years, T1 or T2 stage, absence of synchronous LN metastases, and EBRT. Acute gastrointestinal and bladder reactions were the most common symptoms, but mild non-severe (> grade 3) hematologic symptoms also occurred.
EBRT may improve overall survival for patients with T3/T4 cancer of the renal pelvis or ureter and delay bladder tumour recurrence in all patients.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: After radical nephroureterectomy (RNU), approximately 22% to 47% of patients with upper tract urothelial carcinoma (UTUC) develop a subsequent intravesical recurrence (IVR). Considering this high incidence of occurrence, several risk factors were reported as predictive of IVR after RNU. Until recently, most of the risk factors were still under debate. The aim of study was to conduct a meta-analysis based on the recent literature to explore the risk factors for IVR after RNU for UTUC. Patients and methods: An electronic search of the Med line, Embase, Cochrane Library, Cancer Lit, and databases was performed to identify relevant studies published before May 2013. The studies were included if they reported risk factors related to bladder or IVR after RNU for UTUC. Results: Overall, 40 studies, with 12,010 patients, were included in our meta-analysis. Our study indicated that a statistically significant difference in IVR after RNU was found in the male vs. female patients (odds ratio [OR] = 0.72, 95% CI: 0.59-0.85), ureteral vs. renal pelvis (OR = 1.18, 95% CI: 1.00-1.36), T2-4 vs. Tis, Ta, and Ti (OR = 0.53, 95% CI: 0.40-0.66), larger vs. smaller tumor size (OR = 1.02, 95% CI: 1.01-1.03), and previous/synchronous bladder cancer vs. the absence of bladder cancer (OR = 1.59, 95% CI: 1.26-1.9). No significant differences in IVR after RNU were found in the younger vs. older age groups, multifocal tumors vs. single tumor, G3 vs. G1 and G2, high vs. low grade, NO vs. N+, concomitant carcinoma in situ vs. the absence of carcinoma in situ, positive vs. negative lymphovascular invasion, open vs. laparoscopic nephroureterectomy, and endoscopic vs. transvesical technique. Conclusions: Our study showed that female patient; ureteral tumor; larger tumor; Tis, Ta, and Ti; and the history of bladder cancer were significant risk factors related to IVR after RNU.
    Urologic Oncology 07/2014; 32(7). DOI:10.1016/j.urolonc.2014.01.022 · 3.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 56-year-old male having Grade I transitional cell carcinoma (TCC) of left kidney, postleft nephrectomy and upper 1/3(rd) ureterectomy presented with painless hematuria. Restaging fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) revealed abnormal linear FDG uptake in the lower 2/3(rd) of the left ureter and in the bladder adjacent to the left vesicoureteric junction, no locoregional adenopathy nor distant metastases (Figures 1 and 2- left column). Patient underwent left lower ureterectomy with partial cystectomy. Postoperative histopathology was TCC. Instillation of Bacillus Calmette-Guérin injection in the bladder was done postoperatively. A follow-up FDG PET/CT scan performed 3 months postoperatively was revealed no abnormal focal FDG uptake in the whole body revealing disease free status. FDG PET was helpful in diagnosing tumor recurrence in the distal remnant ureter. This case attempts to highlight the role of FDG PET/CT in follow-up, residual and recurrence evaluation.
    10/2014; 29(4):264-6. DOI:10.4103/0972-3919.142640
  • [Show abstract] [Hide abstract]
    ABSTRACT: Upper tract urothelial carcinoma is more rare than bladder cancer, although they are both categorized as urothelial carcinoma. Because of the low incidence, little clinical evidence is available regarding the treatment of the former. However, recently such evidence has slowly begun to accumulate. The guideline presented herein was compiled for the purpose of ensuring proper diagnosis and treatment by physicians involved in the treatment of upper tract urothelial carcinoma. We carefully selected 16 clinical questions essential for daily clinical practice and grouped them into four major categories: epidemiology, diagnosis, surgery and systemic chemotherapy/other matters. Related literature was searched using PubMed and Japan Medical Abstracts Society databases for articles published between 1987 and 2013. If the judgment was made on the basis of insufficient or inadequate evidence, the grade of recommendation was determined on the basis of committee discussions and resultant consensus statements. Here, we present a short English version of the original guideline, and overview its key clinical issues.
    International Journal of Urology 10/2014; 22(1). DOI:10.1111/iju.12630 · 1.80 Impact Factor

Full-text (4 Sources)

Available from
May 28, 2014